DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms
6 figures., [Background] The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, making it a highly specific and appealing target for CAR-T cell therapy., [Methods] Five distinct CARs were designed based on available monoclonal antibody sequences that target mCALR and were subsequently used to generate CAR-T cells. The most effective construct was selected through functional in vitro assays against mCALR-positive cell lines. Its efficacy was then evaluated in cell lines, patient-derived cells, and orthotopic xenograft models, assessing tumor burden, CAR-T cell infiltration, and animal survival. Bulk and single-cell RNA sequencing were performed on patient-derived cells and residual tumor cells from CART-treated mice, respectively, to investigate potential resistance mechanisms. The impact of the most relevant pathway alteration on CAR-T efficacy was also analyzed. Pharmacological rescue assays using targeted agents were then conducted., [Results] Among the five constructs, one demonstrated superior and specific cytotoxicity against mCALR-expressing cells, with no activity against mCALR-negative controls. This CAR-T cell also eliminated patient-derived MPN cells and controlled disease progression in xenograft models, which correlated with the persistence of CAR-T cells and tumor infiltration. Transcriptomic profiling of patient samples and residual tumor cells in spleens of treated mice revealed upregulation of anti-apoptotic proteins. Functional assays confirmed reduced CAR-T efficacy in Bcl-2 high cells, which was restored by co-treatment with venetoclax, indicating a viable combination approach to overcome resistance., [Conclusions] This study demonstrates, for the first time, the successful targeting of mCALR with CAR-T cells as a therapeutic strategy for MPNs. The chosen construct shows strong preclinical efficacy against established cell lines and patient-derived cells. Additionally, transcriptomic profiling uncovered apoptosis resistance mechanisms and supports a combination strategy with BH3 mimetics, such as venetoclax. These findings provide a compelling rationale for ongoing preclinical development and future clinical application of anti-mCALR CAR-T cells for the treatment of MPNs., This work was funded by the Instituto de Salud Carlos III (ISCIII) through the Strategic Action in Health (AES), 2025 call, Health R&D Projects – Strategic Lines of Health Research (project/grant number: PI25/00236). AR-L is funded by a Ramón y Cajal contract (RYC2022-036627-I), financed by MCIN/AEI/10.13039/501100011033 and the European Social Fund (ESF) “Investing in your future” and ASPANOA. Grant PROY_B61_24 "proyectos de Investigación, desarrollo e innovación (I+D+i) en líneas prioritarias y de carácter multidisciplinar" funded by Gobierno de Aragón to AR-L and DSM. The Instituto de Salud Carlos III (ISCIII) through the Spanish Network of Advanced Therapies (RICORS/TERAV+), project RD24/0014/0015, and co-funded by the European Union (EU) to AR-L, JP, DSM and EMG. Work in the JP laboratory is funded by CIBERINFEC-ConsorcioCentro de Investigación Biomédica en Red- (CB21/13/00087), CERTERA andTERAV+ from Institutode Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional),Gobierno deAragón (Group B29_23R, and LMP139_21), Grants PID2020-113963RBI00 andPID2024-157582OB-I00from MCIN/ AEI/10.13039/501100011033 and private social initiatives(FARO, AECC, Dona Médula, ASPANOA, and Carrera de la Mujer de Monzón No 101018587). Grant PID2022-136554OA-I00 funded by MICIU/AEI 10.13039/501100011033 and the European Regional Development Fund (ERDF)/EU to DSM. Predoctoral Grant for Ibero-Americas in Doctoral studies University of Zaragoza-Santander University (ACP), and Predoctoral Grant from AECC (CP). This work is part of a project that has received funding from the European Research Council (ICoMICS grant agreement No 101018587)., Peer reviewed
Project:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-113963RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2024-2027 PID2024-157582OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-136554OA-I00
,
ERC 101018587
View at: http://hdl.handle.net/10261/418999